The Pfizer-BioNTech vaccine confers moderate protection against COVID-19 in children
1. Two doses of the Pfizer-BioNTech vaccine resulted in moderate protection against SARS-CoV-2 infection in children aged 5 to 11. ...
1. Two doses of the Pfizer-BioNTech vaccine resulted in moderate protection against SARS-CoV-2 infection in children aged 5 to 11. ...
1. This observational cohort study demonstrated that among long-term care residents in Israel, the BNT162b2 (Pfizer-BioNTech) booster dose (third overall ...
1. Three Covid-19 vaccines from Pfizer, Moderna, and Johnson & Johnson provided durable protection against hospitalization and death. 2. However, ...
1. Two doses of Pfizer-BioNTech vaccine were associated with short-term protection against SARS-CoV-2 infection. 2. Infection-acquired immunity plus vaccination provided ...
1. In a large cohort study, infants whose mothers received the BNT162b2 vaccine during pregnancy were not significantly more likely ...
1. Compared to two doses of the BNT162b2 vaccine, a third booster dose was estimated to be 93% effective against ...
1. Despite waning effectiveness against SARS-CoV-2 infection, fully vaccinated patients continued to show low COVID-19 hospitalization rates up to 5 ...
Levels of antibodies against the trimeric spike protein and receptor-binding domain were 36- and 77-fold higher in the BNT162b2 group ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.